A director at Trex Co Inc sold 16,440 shares at 90.905USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
A director at Comfort Systems Usa Inc gave away/sold 1,597 shares at 0.000USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
Martin Marietta Declares Quarterly Cash Dividend RALEIGH, N.C., May 16, 2024 (GLOBE NEWSWIRE) -- Martin Marietta Materials, Inc. (NYSE: MLM) (“Martin Marietta” or the “Company”) today announced that its Board of Directors has declared a regular quarterly cash dividend of $0.74 per share on the Company’s outstanding common stock. This dividend, which represents a cash dividend of $2.96 per share on an annualized basis, is payable June 28, 2024, to shareholders of record at the close of business on June 3, 2024. Martin Marietta, a member of the S&P 500 Index, is an American-based company a...
A director at Simpson Manufacturing Co Inc sold 2,000 shares at 175.130USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
A director at Installed Building Products Inc sold 6,000 shares at 229.841USD and the significance rating of the trade was 77/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last t...
A director at Vulcan Materials Co sold 15,210 shares at 272.812USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
A director at Watsco Inc sold/sold after exercising options 5,334 shares at 466.413USD and the significance rating of the trade was 89/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Morphic to Participate in RBC Capital Markets Global Healthcare Conference WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Marc Schegerin, COO and CFO, will take part in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference on Wednesday, May 15th, at 9:00 AM ET. A live webcast of the panel discussion and fireside chat at the RBC Global Healthcare Conference will be available on the Investor section ...
ADMA Biologics Announces First Quarter 2024 Financial Results and Provides Business Update 1Q 2024 Total Revenue of $81.9 Million, a 44% Increase Y-o-Y 1Q 2024 GAAP Net Income of $17.8 Million, a $24.6 Million Increase Y-o-Y 1Q 2024 Adjusted EBITDA(1) of $26.4 Million, a 970% Increase Y-o-Y FY 2024 and 2025 Total Revenue Guidance Increased to More Than $355 Million and $410 Million, Respectively FY 2024 Net Income Guidance Increased to More Than $85 Million and Adjusted EBITDA Guidance Increased to More Than $110 Million FY 2025 Net Income Guidance Increased to More than $135 Milli...
WINCHESTER, Va.--(BUSINESS WIRE)-- Trex Company, Inc. (NYSE:TREX) (Trex or Company), the world’s #1 brand of high-performance, low-maintenance and eco-friendly composite decking and railing and a leading brand in outdoor living products, today announced financial results for the first quarter of 2024. First Quarter Financial 2024 Highlights Net sales of $374 million Gross margin of 45.4% Net income of $89 million and diluted earnings per share of $0.82 EBITDA of $133 million and EBITDA margin of 35.6% CEO Comments “This was an exceptionally strong quarter for Trex, reflectin...
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now the international nonproprietary name (INN) and United States adopted name (USAN) for XEN1101 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals In...
COLUMBUS, Ohio--(BUSINESS WIRE)-- Installed Building Products, Inc. (the "Company" or "IBP") (NYSE: IBP), an industry-leading installer of insulation and complementary building products, today announced results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights (Comparisons are to Prior Year Period) Net revenue increased 5.1% to $692.9 million Installation revenue increased 5.3% to $655.9 million, as single-family and multi-family sales growth combined with sales from IBP's recent acquisitions Other revenue, which includes IBP’s manufacturing and distribution o...
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024 VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV. Fireside Chat Presentation Details:Date:Wednesday, May 15, 2024Time:3:40 pm Pacific Time (6:40 pm Eastern Time)Webcast:Presenters:Ian Mortimer, President and Chief Executive OfficerSherry Aulin, Chief Financial Of...
Vericel Reports First Quarter 2024 Financial Results and Raises Full-Year 2024 Financial Guidance Total Revenue Increased 25% to $51.3 Million Record First Quarter MACI Revenue of $40.2 Million and Burn Care Revenue Growth of 63% Adjusted EBITDA Growth of 325% Full-Year 2024 Revenue Guidance Raised to $238-$242 Million Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlig...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.